Ozempic vs Mounjaro: Differences, Results, Side Effects, Cost

Ozempic and Mounjaro are both once-weekly injections approved by the FDA for adults with type 2 diabetes, but they are not the same drug. Ozempic is semaglutide, which acts on one gut-hormone receptor (GLP-1). Mounjaro is tirzepatide, which acts on two (GIP and GLP-1). In the one large trial that compared them directly, SURPASS-2, every Mounjaro dose lowered A1C and body weight more than Ozempic 1 mg. Ozempic, in turn, has something Mounjaro does not: proof against placebo that it cuts heart attacks, strokes and kidney failure in people with diabetes, and FDA-approved uses that reflect it. Neither drug is approved for weight loss; their weight-management twins are Wegovy and Zepbound.

This guide compares the two on the points that decide a prescription in real life: what they are approved for, how well they work, side effects, dosing, cost as of October 2026, and who should not take either one. It is information, not medical advice. The choice between them belongs to you and your prescriber.

Ozempic vs Mounjaro at a glance

	Ozempic	Mounjaro
Active ingredient	Semaglutide	Tirzepatide
How it works	GLP-1 receptor agonist	GIP and GLP-1 receptor agonist
Maker	Novo Nordisk	Eli Lilly
FDA-approved uses	Blood sugar control in adults with type 2 diabetes; lowering the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; lowering the risk of kidney function decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease	Blood sugar control in adults and children 10 and older with type 2 diabetes; lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them
Approved for weight loss?	No (same ingredient as Wegovy)	No (same ingredient as Zepbound)
How often	Once a week	Once a week
Starting dose	0.25 mg for 4 weeks	2.5 mg for 4 weeks
Maintenance doses	0.5 mg, 1 mg or 2 mg	5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg
Maximum dose	2 mg weekly	15 mg weekly (10 mg for ages 10 to 17)
Also sold as a pill?	Yes, Ozempic tablets (1.5, 4 and 9 mg, once daily)	No
Boxed warning	Thyroid C-cell tumors	Thyroid C-cell tumors
List price	About $1,028 per pen (one month)	$1,112.16 per month (four pens)

Sources: current FDA prescribing information for both drugs and the manufacturers' pricing pages, checked October 14, 2026.

How they work: one hormone target or two

After you eat, your gut releases hormones called incretins. Two of them matter here. GLP-1 tells the pancreas to release insulin when blood sugar is high, lowers glucagon, slows how fast the stomach empties and acts on appetite centers in the brain. GIP also boosts insulin release after meals and appears to play a part in how the body handles fat and appetite.

Semaglutide, the ingredient in Ozempic, is built to copy GLP-1 and nothing else. Tirzepatide, the ingredient in Mounjaro, is a single molecule that activates both the GIP and the GLP-1 receptors. That is why you will see Mounjaro described as a "dual agonist" or "twincretin." Strictly speaking, it is not just a GLP-1 drug, although pharmacies, insurers and most headlines group it with them.

Whether the second target explains Mounjaro's stronger numbers is still debated among researchers. What is settled is the result of the head-to-head comparison, not the mechanism behind it. For a deeper look at the two molecules themselves, see semaglutide vs tirzepatide.

Which works better for blood sugar and weight

The cleanest answer comes from SURPASS-2, published in the New England Journal of Medicine in 2021. It enrolled 1,879 adults with type 2 diabetes who were already taking metformin and assigned them to Mounjaro 5 mg, 10 mg or 15 mg, or to Ozempic 1 mg, for 40 weeks. The figures below are the ones printed in Mounjaro's FDA label.

Result at 40 weeks	Ozempic 1 mg	Mounjaro 5 mg	Mounjaro 10 mg	Mounjaro 15 mg
Starting A1C	8.3%	8.3%	8.3%	8.3%
Change in A1C (points)	-1.9	-2.0	-2.2	-2.3
Reached A1C below 7%	79%	82%	86%	86%
Change in body weight	-5.7 kg (about 12.6 lb)	-7.6 kg (about 16.8 lb)	-9.3 kg (about 20.5 lb)	-11.2 kg (about 24.7 lb)

Three things are worth knowing before you read too much into that table.

• The comparison stopped at Ozempic 1 mg. The 2 mg dose was approved later. In a separate trial, SUSTAIN FORTE, Ozempic 2 mg lowered A1C by 2.2 points and weight by 6.9 kg over 40 weeks, compared with 1.9 points and 6.0 kg on 1 mg. That narrows the gap with the lowest Mounjaro doses, but no trial has put Ozempic 2 mg against Mounjaro directly.
• Both drugs worked well. Nearly eight in ten people on Ozempic reached an A1C under 7%. The difference between the drugs is real, but it is a difference between two effective medicines.
• Averages hide individuals. Some people respond better to semaglutide, some tolerate one drug and not the other, and your own result cannot be predicted from a trial mean.

For weight specifically, the evidence in people without diabetes points the same way. In SURMOUNT-5, a 72-week trial of 751 adults with obesity, tirzepatide produced an average weight loss of 20.2% compared with 13.7% for semaglutide at their weight-management doses. That trial used the Zepbound and Wegovy versions, covered in Wegovy vs Zepbound. A large study of U.S. health records published in JAMA Internal Medicine in 2024 found the same pattern in everyday practice.

Heart and kidney protection: where Ozempic has the longer record

Lowering A1C is one goal of diabetes treatment. Preventing heart attacks, strokes and dialysis is the bigger one, and here the two drugs have different kinds of evidence.

• Ozempic and the heart. In SUSTAIN-6, a trial of 3,297 people with type 2 diabetes at high cardiovascular risk, major cardiovascular events occurred in 6.6% of those on semaglutide and 8.9% on placebo (hazard ratio 0.74). The label carries a cardiovascular indication for adults with type 2 diabetes and established cardiovascular disease.
• Ozempic and the kidneys. In FLOW, a trial of 3,533 people with type 2 diabetes and chronic kidney disease, semaglutide 1 mg lowered the risk of major kidney outcomes and cardiovascular death by 24% compared with placebo. Ozempic is the only one of the two with a kidney indication.
• Mounjaro and the heart. Mounjaro gained its cardiovascular indication in August 2026 on the strength of SURPASS-CVOT, which followed 13,299 people with type 2 diabetes and cardiovascular disease for a median of about four years. It was compared with another proven drug, dulaglutide (Trulicity), not placebo. Mounjaro was non-inferior, with a hazard ratio of 0.92; the label states plainly that superiority to dulaglutide was not established.

In practice, that means both medicines now have FDA-approved cardiovascular uses, Ozempic's evidence is against placebo and older, and Ozempic alone is labeled for diabetic kidney disease. If you have kidney disease or have already had a heart attack or stroke, raise that directly with your prescriber, because it can tip the choice.

Side effects compared

The two drugs share a side-effect profile because they share a mechanism. Stomach and bowel symptoms lead the list for both, appear mostly while the dose is being raised, and tend to settle. These are the rates from the placebo-controlled trials summarized in each label; they come from different studies, so read them as a guide rather than a scoreboard.

Side effect	Ozempic 0.5 mg	Ozempic 1 mg	Mounjaro 5 mg	Mounjaro 10 mg	Mounjaro 15 mg
Nausea	15.8%	20.3%	12%	15%	18%
Diarrhea	8.5%	8.8%	12%	13%	17%
Vomiting	5%	9.2%	5%	5%	9%
Constipation	5%	3.1%	6%	6%	7%
Abdominal pain	7.3%	5.7%	6%	5%	5%
Decreased appetite	not listed	not listed	5%	10%	11%

When the drugs were tested against each other in SURPASS-2, the picture was similar across arms: nausea in 17% to 22% of people on Mounjaro and 18% on Ozempic, diarrhea in 13% to 16% versus 12%, and vomiting in 6% to 10% versus 8%. Serious adverse events were reported in 5% to 7% of the Mounjaro groups and 3% of the Ozempic group.

The serious warnings in the two labels overlap almost entirely: pancreatitis, gallbladder problems, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from dehydration, severe gastrointestinal reactions, serious allergic reactions, worsening of diabetic eye disease in people who already have it, and a risk of inhaling stomach contents during anesthesia or deep sedation.

Call your prescriber promptly for vomiting or diarrhea that will not stop, signs of dehydration, or changes in vision. Get emergency care or call 911 for severe abdominal pain that does not go away (with or without vomiting), swelling of the face, lips or throat, or trouble breathing.

Dosing schedules side by side

Both drugs are stepped up slowly to give the gut time to adjust. Neither starting dose is meant to control blood sugar; it is there for tolerability.

Step	Ozempic	Mounjaro
Weeks 1 to 4	0.25 mg	2.5 mg
Weeks 5 to 8	0.5 mg	5 mg
If more control is needed	1 mg after at least 4 weeks on 0.5 mg	Increase by 2.5 mg after at least 4 weeks on the current dose
Further steps	2 mg after at least 4 weeks on 1 mg	7.5, 10, 12.5 and 15 mg
Fastest route to the top dose	About 13 weeks	About 21 weeks
Missed dose	Take within 5 days; otherwise skip	Take within 4 days (96 hours); otherwise skip
Changing your injection day	Allowed if doses are at least 2 days apart	Allowed if doses are at least 3 days apart
Where to inject	Abdomen, thigh or upper arm	Abdomen or thigh; back of the upper arm if someone else injects

The devices differ too. The usual Ozempic pen holds several weekly doses; you attach a new needle each time and dial the dose. Mounjaro most often comes as a carton of four single-dose auto-injector pens with a hidden needle, one pen per week. Mounjaro's current label also covers vials and a four-dose KwikPen.

One practical difference that surprises people: Mounjaro's label advises anyone using birth control pills to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase, because tirzepatide can reduce how well oral contraceptives are absorbed. Ozempic's label has no equivalent instruction.

There is no official conversion between the two. If you are moving from one to the other, your prescriber sets the starting dose; the reasoning and the published guidance are in switching from Ozempic to Mounjaro.

Cost with and without insurance

Prices below were checked on the manufacturers' own pages on October 14, 2026. They change often, and the introductory offers have end dates.

	Ozempic	Mounjaro
List price	$1,027.51 per pen	$1,112.16 per month
Commercial insurance that covers it, with the savings card	As little as $25 a month (maximum savings $100 a month)	As little as $25 for a 1-, 2- or 3-month fill (maximum savings $150 a month, $1,950 a year)
Commercial insurance that does not cover it	Self-pay price applies	As low as $499 a month with the savings card
Self-pay, direct from the manufacturer	NovoCare Pharmacy: $199 a month for the first two fills of 0.25 mg or 0.5 mg (new patients, offer runs through December 31, 2026), then $349 a month for 0.25, 0.5 or 1 mg and $499 a month for 2 mg	LillyDirect: single-dose pens starting at $499 a month, all strengths
Medicare, Medicaid, TRICARE, VA	Not eligible for the savings card; coverage for type 2 diabetes depends on the plan	Not eligible for the savings card; coverage for type 2 diabetes depends on the plan

For someone paying cash, Ozempic is currently the cheaper of the two at most doses. With commercial coverage and a savings card, both can come down to $25. Medicare Part D plans generally cover both for type 2 diabetes, with your cost set by the plan's formulary tier and deductible; they are not part of the $50-a-month Medicare GLP-1 Bridge, which is limited to weight-management drugs. Both Mounjaro's savings card and the Ozempic introductory offer are scheduled to end on December 31, 2026 unless the companies extend them. The full breakdown, including Wegovy, Zepbound and the pills, is in GLP-1 cost without insurance.

Who should not take Ozempic or Mounjaro

Both labels open with the same boxed warning, the FDA's strongest. In rodents, semaglutide and tirzepatide caused thyroid C-cell tumors. It is not known whether they cause these tumors, including medullary thyroid carcinoma (MTC), in humans.

Neither drug should be used by anyone who has:

• a personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• a previous serious allergic reaction to the drug or its ingredients

Tell your prescriber before starting either one if you have had pancreatitis, have diabetic retinopathy, kidney problems, gastroparesis or other severe stomach problems, or if you are pregnant, planning a pregnancy or breastfeeding. Ozempic's label says to stop the drug at least two months before a planned pregnancy. Both labels say to tell your surgical team you take the medicine before any procedure involving anesthesia or deep sedation. Neither drug is for type 1 diabetes, and neither should be combined with another GLP-1 medicine.

Report a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath to your doctor; these can be symptoms of a thyroid tumor.

Ozempic or Mounjaro: how prescribers tend to choose

There is no universal winner, and you should be wary of any article that names one. These are the considerations that usually drive the decision.

• You need the largest drop in A1C or weight: the head-to-head data favor Mounjaro.
• You have chronic kidney disease with type 2 diabetes: Ozempic is the one with an FDA-approved kidney indication.
• You have established cardiovascular disease: both are now labeled to lower cardiovascular risk; Ozempic's evidence against placebo is longer-standing.
• You would rather not inject: Ozempic now comes as a daily tablet for type 2 diabetes. Mounjaro has no pill form. See GLP-1 pills compared.
• You take birth control pills: Mounjaro requires backup contraception around each dose change.
• Your child has type 2 diabetes: Mounjaro is approved from age 10; Ozempic is approved for adults only.
• Your insurance prefers one: many formularies do, and that often settles it. Prior authorization usually requires a type 2 diabetes diagnosis for either drug.
• Your goal is weight loss without diabetes: the on-label options are Wegovy, Zepbound and the newer pills, not Ozempic or Mounjaro. Start with the best GLP-1 for weight loss.

The same drugs under other names

Much of the confusion around this comparison comes from branding. Two molecules are sold under five injectable and pill brand names, each with its own approved use.

Brand	Ingredient	Main approved use	Compared in
Ozempic	Semaglutide	Type 2 diabetes	Ozempic vs Wegovy
Wegovy	Semaglutide	Weight management, cardiovascular risk, MASH	Wegovy vs Zepbound
Mounjaro	Tirzepatide	Type 2 diabetes	Mounjaro vs Zepbound
Zepbound	Tirzepatide	Weight management, obstructive sleep apnea	Zepbound vs Ozempic
Rybelsus / Ozempic tablets	Semaglutide (oral)	Type 2 diabetes	GLP-1 pills compared

You may also see skin patches marketed with "GLP-1" on the label. Those are supplements, not semaglutide or tirzepatide; our guide to GLP-1 patches explains what they are and what they are not.

What happens if you stop

Type 2 diabetes is a long-term condition, and both medicines work only while you take them. Blood sugar generally rises again after stopping. The weight data tell the same story: in the STEP 1 extension, people who stopped semaglutide 2.4 mg regained about two-thirds of the weight they had lost within a year, and in SURMOUNT-4, people switched from tirzepatide to placebo regained a substantial share while those who continued kept losing. Do not stop or skip doses to stretch a supply without talking to your prescriber, and ask about a plan if cost or a shortage at your pharmacy interrupts treatment.